CLINICAL TRIALS PROFILE FOR MERCAPTOPURINE

All Clinical Trials for MERCAPTOPURINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	Medical Research Council	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	National Cancer Institute (NCI)	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	Eastern Cooperative Oncology Group	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002531 ↗	Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia	Unknown status	Johann Wolfgang Goethe University Hospital	Phase 2	1993-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of various combination chemotherapy regimens in treating patients with acute lymphocytic leukemia.
NCT00002618 ↗	Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	1994-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different doses may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with various combinations of drugs in treating pediatric patients with advanced-stage large cell lymphoma.
NCT00002618 ↗	Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma	Completed	Children's Oncology Group	Phase 3	1994-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different doses may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with various combinations of drugs in treating pediatric patients with advanced-stage large cell lymphoma.

Clinical Trial Conditions for MERCAPTOPURINE

Condition Name

Condition Name for MERCAPTOPURINE
Intervention	Trials
Leukemia	63
Acute Lymphoblastic Leukemia	51
Ulcerative Colitis	16
Crohn's Disease	15

Condition MeSH

Condition MeSH for MERCAPTOPURINE
Intervention	Trials
Leukemia	161
Precursor Cell Lymphoblastic Leukemia-Lymphoma	156
Leukemia, Lymphoid	146
Lymphoma	36

Clinical Trial Locations for MERCAPTOPURINE

Trials by Country

Trials by Country for MERCAPTOPURINE
Location	Trials
Canada	241
Australia	91
Spain	44
France	37
Germany	34

Trials by US State

Trials by US State for MERCAPTOPURINE
Location	Trials
Texas	77
California	72
New York	64
Tennessee	62
Illinois	59

Clinical Trial Progress for MERCAPTOPURINE

Clinical Trial Phase

Clinical Trial Phase for MERCAPTOPURINE
Clinical Trial Phase	Trials
PHASE3	2
PHASE2	9
PHASE1	2

Clinical Trial Status

Clinical Trial Status for MERCAPTOPURINE
Clinical Trial Phase	Trials
Completed	120
Recruiting	44
Active, not recruiting	23

Clinical Trial Sponsors for MERCAPTOPURINE

Sponsor Name

Sponsor Name for MERCAPTOPURINE
Sponsor	Trials
National Cancer Institute (NCI)	77
Children's Oncology Group	32
St. Jude Children's Research Hospital	15

Sponsor Type

Sponsor Type for MERCAPTOPURINE
Sponsor	Trials
Other	343
NIH	84
Industry	72

Mercaptopurine: Clinical-Development Update, Market Analysis, and Projections

Last updated: April 28, 2026

What is mercaptopurine’s current clinical development footprint?

Mercaptopurine (6-mercaptopurine; 6-MP) is a long-established antimetabolite used in oncology and inflammatory bowel disease (IBD). Its clinical profile is defined largely by long-term standards of care, rather than late-stage, registrational-grade modern trials.

Trial activity signal (registry):

• Clinical trial publication cadence is dominated by:
  • regimen comparisons,
  • therapeutic drug monitoring (TPMT/6-TGN),
  • toxicity management (especially myelosuppression),
  • pediatric/maintenance outcomes in acute lymphoblastic leukemia (ALL),
  • and post-therapy survivorship or safety studies.
• Late-stage phase 3 “new indication” efforts are not a dominant feature versus historical evidence and evolving standard-of-care protocols.

Practical interpretation for R&D and investment:

• The development value for mercaptopurine is mostly in formulation, dosing optimization, and biomarkers/monitoring strategies rather than novel MOA.
• In-market differentiation tends to be:
  • reduced variability of exposure,
  • improved adherence/tolerability,
  • and more precise individualized dosing using TPMT genotype and metabolite assays (6-TGN, 6-MMP).

What endpoints and evidence themes dominate mercaptopurine studies?

The recurring clinical endpoints in mercaptopurine trials and monitoring studies include:

• hematologic toxicity rates (neutropenia, leukopenia, infection burden)
• time to treatment interruption/discontinuation
• event-free survival (EFS) and relapse rates in leukemia maintenance settings
• metabolite exposure targets (6-TGN) and dose-response curves
• adherence and bioavailability under real-world conditions
• treatment-limiting adverse events (TLAEs), including hepatic toxicity

Mechanistic standard-of-care frame (why these endpoints persist):

• Mercaptopurine is converted to active thioguanine nucleotides; exposure correlates with both efficacy and toxicity.
• TPMT genetic status and metabolite profiles drive dosing decisions in many protocols. (Clinical pharmacology foundation is reflected in labeling and consensus practice.)

What do the labels and safety foundations imply for near-term trial design?

Clinical programs for mercaptopurine typically align with long-standing constraints:

• narrow therapeutic window in maintenance regimens
• dose titration based on blood counts and (in some workflows) thiopurine metabolite levels
• treatment interruption and supportive care strategies for myelosuppression
• hepatic monitoring requirements

These constraints bias trial designs toward:

• pharmacology and safety optimization,
• monitoring algorithms,
• and protocol refinements rather than transformative clinical claims.

---

How big is the mercaptopurine market today?

Mercaptopurine market size is driven by:

• pediatric and adult ALL maintenance therapy use (where thiopurines are part of standard regimens)
• IBD maintenance prescribing (in combination with other agents in many lines of therapy)
• generic availability which structurally caps pricing and brand premium

Market structure facts:

• Mercaptopurine is widely available as generics in major markets.
• Patent exclusivity is not a growth driver because off-patent supply dominates procurement dynamics.
• The market is therefore mostly volume-driven (patient numbers and guideline adherence) with modest pricing headroom.

Commercial implications:

• Any growth largely depends on:
  • stable incidence of treated ALL and IBD,
  • protocol intensity and persistence,
  • substitution patterns between thiopurines,
  • and uptake of dosing/monitoring approaches that preserve adherence.

---

What are the market projections through the next 5 years?

Given generic penetration, mercaptopurine’s forecast is usually characterized by:

• stable-to-slightly growing volume,
• soft pricing pressure,
• and incremental shifts in share based on:
  • supply reliability,
  • formulary inclusion,
  • and treatment line preferences (azathioprine vs mercaptopurine, where clinically appropriate).

Projection profile (directional):

• Base case: market largely tracks treated patient volume with pricing declines or flat pricing.
• Downside: protocol shifts away from thiopurines in some IBD lines and improved toxicity management reducing total exposure intensity can reduce net demand.
• Upside: increased use of thiopurines where biologic or targeted therapy access is constrained, plus guideline-driven maintenance continuity.

What would move the numbers materially?

• Regulatory or guideline changes that increase thiopurine adoption in first-line or maintenance settings.
• Major manufacturing supply disruptions that shift procurement to alternative suppliers (not the total market size, but short-term revenue and ordering patterns).

Because mercaptopurine is off-patent in most geographies, projections should be treated as volume and procurement forecasts rather than innovation-led expansion.

---

Where does mercaptopurine create opportunity vs competitive substitutes?

Key therapeutic competitors and substitution dynamics:

• Azathioprine (IBD): often the first thiopurine used; mercaptopurine can capture patients with azathioprine intolerance or non-response.
• Methotrexate and biologics (IBD): compete for maintenance lines; thiopurines retain a role where cost, tolerability, or escalation pathways support them.
• Other leukemia maintenance regimens: pegylated asparaginase and different backbone structures can reduce thiopurine intensity depending on protocol evolution.

Differentiation levers that can affect share even in generics:

• consistent supply and fewer shortages
• dosing convenience (strengths and formulations)
• clinician familiarity and TDM availability infrastructure
• payer formulary stability

---

How does the IP landscape affect R&D strategy for mercaptopurine?

Mercaptopurine has a legacy IP profile with modern brand-building limited by generic supply. For investors and R&D teams, this shifts the opportunity set toward:

• reformulation (if it improves tolerability, stability, or administration)
• long-acting delivery (rare for mercaptopurine in practice because the clinical standard depends on tight dosing and monitoring)
• companion diagnostics and dosing algorithms (TPMT genotype, metabolite monitoring frameworks)

Net effect: clinical development is more compatible with “productivity innovation” than with new-molecule registrational pathways.

---

Key Takeaways

• Mercaptopurine’s clinical activity is dominated by optimization studies (monitoring, dosing, toxicity management) rather than late-stage new-indication development.
• Market performance is volume-driven due to generic availability, with revenue sensitivity to pricing pressure and procurement patterns.
• Projections through the next 5 years are most likely stable-to-slightly growing in volume with flat or declining net pricing, absent major guideline-driven shifts.
• Near-term opportunity for commercial and R&D teams is centered on TPMT/metabolite-informed dosing workflows, formulary execution, and supply reliability rather than MOA novelty.

---

FAQs

1) Does mercaptopurine have meaningful new late-stage development in its core markets?

Clinical activity is mainly optimization-oriented (safety, dosing, monitoring) rather than a dominant late-stage registrational pattern.

2) What determines mercaptopurine dosing most often in practice?

TPMT genotype and blood count response drive many dosing workflows; some settings incorporate thiopurine metabolite targets.

3) What drives mercaptopurine demand outside oncology?

IBD maintenance prescribing is a major driver, though competitive pressure from other immunomodulators and biologics can shift demand.

4) How do generic dynamics affect market projections?

They compress pricing and make forecasts depend primarily on treated patient volume, adherence, and formulary inclusion.

5) What are the highest-impact commercialization levers for an off-patent drug?

Supply reliability, predictable procurement, dosing convenience, and compatibility with monitoring programs (TDM infrastructure).

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. (Search results and study records for mercaptopurine). https://clinicaltrials.gov/
[2] FDA. Mercaptopurine prescribing information (labeling and safety/monitoring guidance). https://www.accessdata.fda.gov/
[3] EMA. Therapeutic use and product information for mercaptopurine (SmPC and safety sections). https://www.ema.europa.eu/